Condition
Fetal and Neonatal Alloimmune Thrombocytopenia
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed3
Unknown1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06435845Phase 2TerminatedPrimary
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT05345561CompletedPrimary
Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
NCT04067375CompletedPrimary
Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
NCT04529382UnknownPrimary
Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
NCT03561909Not ApplicableCompletedPrimary
Kinetics of Blood Platelets Transfused to Healthy Subjects
Showing all 5 trials